Sign In
Last checked at 
13 May 2010 15:37
ο»Ώ
Β
Hikma Pharmaceuticals PLC - Results of Annual General Meeting
Β
LONDON, 13 May 2010 - Hikma Pharmaceuticals PLC ("the Company") advises that at its Annual General Meeting of shareholders, held at Regus, Berkeley Square House, Berkeley Square, London, W1J 6BD that commenced at 10.30am today, 13 May 2010, all resolutions were passed on a poll. Resolutions 1 to 7, 12 to 14 were passed as ordinary resolutions and Resolutions 8 to 11 were passed as special resolutions.
Β
Copies of the resolutions dealing with special business passed at the Annual General Meeting have been submitted to the UK Listing Authority for publication through the Listing Authority's Document Viewing Facility.
Β
The total number of votes cast on the poll for each resolution is set out below. The number of Ordinary Shares in issue on 13 May 2010 was 193,157,089.
Β
|
Β |
Resolution |
Votes Β For |
% |
Votes Against |
% |
Votes Witheld |
|
1 |
To receive the 2009 report and accounts |
131,882,578 |
99.64 |
481,335 |
0.36 |
2,588,508 |
|
2 |
To declare a final dividend |
132,460,913 |
100 |
3,000 |
0 |
2,488,508 |
|
3 |
Reappointment of Dr Ronald Goode |
132,331,360 |
99.9 |
132,553 |
0.1 |
2,488,508 |
|
4 |
Reappointment of Deloitte LLP as auditors |
131,727,953 |
99.44 |
735,960 |
0.56 |
2,488,508 |
|
5 |
Authorise the directors to set the remuneration of the auditors |
131,614,903 |
99.36 |
848,960 |
0.64 |
2,488,558 |
|
6 |
To receive and approve the Remuneration Report |
131,100,850 |
99.59 |
542,368 |
0.41 |
3,313,603 |
|
7 |
Authorise the directors to allot shares |
111,441,185 |
84.57 |
20,338,113 |
15.43 |
3,173,123 |
|
8 |
Disapply pre-emption rights |
132,457,707 |
100 |
5,706 |
0 |
2,489,008 |
|
9 |
Authorise the company to buy back shares |
132,416,818 |
99.96 |
46,595 |
0.04 |
2,489,008 |
|
10 |
Authorise the company to call meetings on 14 days notice |
129,861,252 |
98.04 |
2,602,661 |
1.96 |
2,488,508 |
|
11 |
Amend the Articles of Association |
130,247,774 |
98.33 |
2,215,639 |
1.67 |
2,489,008 |
|
12 |
Amendment of MIP rules |
129,623,337 |
99.40 |
777,065 |
0.60 |
4,552,019 |
|
13 |
Rule 9 waiver for buy backs |
106,036,546 |
82.25 |
22,888,095 |
17.75 |
6,027,780 |
|
14 |
Rule 9 waiver for LTIP & MIP awards |
106,035,446 |
82.25 |
22,889,195 |
17.75 |
6,027,780 |
Β
Β
Waiver of Rule 9 of the City Code on Takeovers and Mergers
Β
In relation to Resolutions 13 and 14, at today's date, the total number of ordinary shares held by the Concert Party, is 65,786,008 representing a combined shareholding of 34.06 per cent of the issued share capital of the Company.
Assuming the Share Awards are made in respect of the full number of shares referred to in the circular to shareholders dated 9 April 2010, that all such grants vest in full, and that all existing awards LTIP Awards vest in full, and that all Options currently held by members of the Concert Party were to be fully exercised and the resulting Ordinary Shares retained by the Concert Party members, the Concert Party would hold, in aggregate, interests over 66,889,554 Ordinary Shares, representing 34.63 per cent of the issued share capital of the Company (as enlarged by the existing LTIP Awards and Option Exercises by members of the Concert Party and the issue of Ordinary Shares to members of the Concert Party pursuant to the Share Awards, but assuming no other issue of shares) versus 34.84 per cent of the issued share capital of the Company on a similar basis, prior to the grant of such Share Awards.
Were the Company to exercise the buy-back authority to the exclusion of the Concert Party such that the Concert Party maintained its current shareholding, that would result in the Concert Party's percentage interest in the Company's issued share capital increasing 38.47 per cent. (assuming that all Existing LTIP Awards vest in full and all Options held by members of the Concert Party are exercised and the resulting Ordinary Shares are retained, but not including the Share Awards granted under Resolution 14).
Β
If the maximum repurchase of Ordinary Shares authorised was carried out by the Company and also the maximum number of Share Awards vested, together with the Existing LTIP Awards and Option Exercises these changes would increase the aggregate shareholding of the Concert Party in the Company to 38.70 per cent. (assuming that that the Concert Party did not sell any Ordinary Shares in the repurchase of Ordinary Shares and assuming no other issue of Ordinary Shares).
Declaration of final dividend
The final dividend of 6.5 cents per share will be paid on 27 May 2010 to shareholders on the register on 16 April 2010. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend is 1.4785 US dollars to one Pound Sterling, equal to approximately 4.4 Pence per share. Shareholders resident in Jordan have been given the opportunity to receive the dividend in Jordanian Dinar, at a rate of 0.708 Jordanian Dinar per US dollar.
- ENDS -
Enquiries:
Β
|
Hikma Pharmaceuticals PLC |
||
|
Henry Knowles Company Secretary Β |
+44 20 7399 2670 |
|
|
Susan Ringdal Investor Relations Director Β |
+44 20 7399 2670 Β |
|
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2009, Hikma achieved revenues of $637 million and profit attributable to shareholders of $78 million. For news and other information, please visit www.hikma.com.
Β
Β
Β
Β
Follow the stocks
